Annual Scientific Meeting

Visit GI Cancer Trials 

Abstract submission

The ASM Executive Committee is pleased to invite the submission of abstracts for consideration in the 2026 ASM program.

All accepted abstracts will be presented in poster format and displayed throughout the ASM. In addition, a limited number of abstracts may be selected for:


The final selection of abstracts for both oral presentation formats will be made by the ASM Executive Committee. During the abstract submission process, you will have the opportunity to indicate if you wish to be considered for an oral presentation during the submission process.

The abstract submission portal has now closed. Notifications of abstract outcomes are expected to be sent on Monday, 21 September 2026.

For any enquiries, please contact GI Cancer Trials.

Submission guidelines

Terms and conditions

  • Abstracts must be submitted via the online submission portal. There is no limit in the number of abstracts that may be submitted by each author
  • The presenting author must be a GI Cancer Trials member, registered as a fully paid delegate, and attend the ASM in person. Registration can be completed after abstract acceptance is notified. If the presenting author cannot attend at the scheduled date and time, an alternate may be nominated in writing to GI Cancer Trials
  • Industry-sponsored studies must be presented by a GI Cancer Trials member who has had significant involvement in the study
  • The submitting author is responsible for the accuracy of all submitted information and must ensure that all co-authors have reviewed and approved the abstract
  • Encore abstracts (i.e., previously presented at another scientific meeting) are permitted but must be clearly disclosed at the time of submission
  • Accepted abstracts will be published in the Asia-Pacific Journal of Clinical Oncology (Wiley Online) following the ASM. Submitting authors are therefore encouraged to carefully review their abstract details prior to submission. Those who do not wish for their abstracts to be published must indicate this at the time of submission
  • All abstracts will undergo a blinded review process. The decision of the ASM Executive Committee is final
  • Personal information provided during the abstract submission process will be used for conference administration and communication purposes

Abstract content

Each submitted abstract must include the following elements in sentence case (i.e. upper and lower case):

  • Title (maximum of 30 words)
  • Author names (all authors must be listed in full with the presenting author identified at the time of submission)
  • Affiliation(s)
  • Abstract text (maximum of 300 words; no images or tables; structured as Background, Methods, Results, and Conclusions)

Additional information

  • An acknowledgement email will be sent to the submitting author upon submission. If you do not receive this email, please check your spam folder before contacting GI Cancer Trials
  • Only submitting authors will be notified of the abstract selection outcome

Acceptance criteria

Abstracts will be accepted based on the following criteria:

Poster presentation guidelines

  • All posters must be in A0 portrait format (84.1 cm wide × 118.9 cm high)
  • Poster printing and delivery to the ASM are the responsibilities of the presenter
  • Velcro for mounting posters will be available at the ASM Registration Desk
  • Dismantling of posters at the end of the ASM is the responsibility of the presenter
  • Detailed presentation instructions will be provided in the notification of acceptance

For any difficulties or to make changes to your abstract after submission, please contact GI Cancer Trials.